Hims stock dropped sharply Friday after the U.S. Food and Drug Administration said the shortage of widely-used weight-loss and diabetes drugs has been resolved.
The FDA website indicated that the shortage of Novo Nordisk's Ozempic and Wegovy has ended. The announcement is bad news for Hims & Hers, a compounding pharmacy that makes a knockoff version of Wegovy.
In December, the FDA said Eli Lilly (LLY) drugs Mounjaro and Zepbound were no longer in shortage.
↑ X NOW PLAYING Nvidia Earnings Preview: Blackwell, DeepSeek And Big ExpectationsHims (HIMS) stock crashed nearly 20% to 53.38 in morning trades after hitting a record 72.98 on Wednesday. Shares of Novo Nordisk (NVO) rallied 5.1% to 88.03, just below a long-sliding 50-day line. Eli Lilly stock rose 1.7% to 888, near an 889.36 handle buy point.
Hims stock, which has rallied more than 120% this year, is on track to record its first weekly loss in six weeks, according to IBD MarketSurge. The shares have had a strong Relative Strength rating of 99.
The news underlines the role played by compounders, companies allowed to create knockoffs of drugs to offset shortages, in the fast-growing weight-loss drugs industry.
Hims & Hers also recently took some heat for a Super Bowl ad that does not include any warnings about the side effects of Wegovy.
Him & Hers will report Q4 results on Monday.
YOU MAY ALSO LIKE:
Get Timely Buy & Sell Alerts With IBD Leaderboard
Uber Stock Eyes Bounce Back As Robotaxi Strategy Faces Big Test
Which Stocks Are Breaking Out Or Near A Pivot Point? Check MarketSurge
Nvidia Stock Pauses Despite Debut Of Blackwell. What The King Of AI Chips Needs Now.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。